Your browser doesn't support javascript.
loading
Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study.
Jacot, W; Firmin, N; Roca, L; Topart, D; Gallet, S; Durigova, A; Mirr, S; Abach, L; Pouderoux, S; D'Hondt, V; Bleuse, J P; Lamy, P J; Romieu, G.
Afiliación
  • Jacot W; Department of Medical Oncology William.Jacot@icm.unicancer.fr.
  • Firmin N; Department of Medical Oncology.
  • Roca L; Biometrics Unit, Institut régional du Cancer de Montpellier (ICM), Montpellier.
  • Topart D; Department of Medical Oncology, CHU de Montpellier, Montpellier.
  • Gallet S; Department of Medical Oncology.
  • Durigova A; Department of Medical Oncology.
  • Mirr S; Department of Medical Oncology.
  • Abach L; Biometrics Unit, Institut régional du Cancer de Montpellier (ICM), Montpellier.
  • Pouderoux S; Department of Medical Oncology.
  • D'Hondt V; Department of Medical Oncology.
  • Bleuse JP; Biometrics Unit, Institut régional du Cancer de Montpellier (ICM), Montpellier.
  • Lamy PJ; Specialized Biology and Oncogenetics Laboratory, Institut régional du Cancer de Montpellier (ICM), Montpellier, France.
  • Romieu G; Department of Medical Oncology.
Ann Oncol ; 27(7): 1235-41, 2016 07.
Article en En | MEDLINE | ID: mdl-27029707
BACKGROUND: A minority of early breast cancer (EBC) patients treated with adjuvant or neoadjuvant chemotherapy have sufficient baseline vitamin D (vitD) level. This randomized phase III study assessed the safety and efficacy of a tailored, high-dose, oral vitD supplementation in restoring a normal 25-hydroxy vitD (25OHD) level in this population. PATIENTS AND METHODS: Participants received a 6-month conventional (C) vitD and calcium supplementation or a 6-month high-dose oral vitD regimen tailored on the deficiency (T) and a conventional calcium supplementation. The primary end point was the 6-month percentage of 25OHD serum level normalization. RESULTS: A total of 215 patients including 197 patients with vitD deficiency were recruited, and 195 patients were randomized (T, 100; C, 95). Compliance to the daily oral supplementation was 68.4% and 67% in the C and T arms, respectively. Discontinuous high-dose vitD compliance appeared higher in the T arm (77%). At 6 months, more patients presented with a normalized vitD level in the T arm (30% versus 12.6%; P = 0.003). Supplementation was well tolerated, and no significant difference in the treatment-related toxicity between the two arms was reported. Fifty-two patients without vitD normalization from the C arm switched to the T arm after 6 months. At 12 months, 44% of these patients achieved vitD normalization. CONCLUSION: A tailored high-dose oral vitD supplementation safely allows a higher percentage of the serum 25OHD level normalization compared with a conventional regimen in chemotherapy-treated EBC patients. As compliance to a daily oral supplementation remains poor in this setting, an adaptation of the treatment schedule is warranted. CLINICAL TRIAL NUMBER: NCT01480869.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vitamina D / Deficiencia de Vitamina D / Neoplasias de la Mama / Suplementos Dietéticos Tipo de estudio: Clinical_trials Aspecto: Patient_preference Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vitamina D / Deficiencia de Vitamina D / Neoplasias de la Mama / Suplementos Dietéticos Tipo de estudio: Clinical_trials Aspecto: Patient_preference Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article Pais de publicación: Reino Unido